Arrivent Biopharma, Inc. — 2023 Form 10-K Summary
Business context and reporting period
Arrivent is a clinical-stage biopharmaceutical company focused on oncology medicines, particularly non-small cell lung cancer (NSCLC). The fiscal year ended December 31, 2023. The company has no approved products or product revenue and depends primarily on furmonertinib, an investigational EGFR tyrosine kinase inhibitor licensed from Shanghai Allist Pharmaceuticals for development and commercialization outside Greater China.
- Furmonertinib is approved and commercialized by Allist in China for certain classical EGFR-mutated NSCLC indications, but is not approved by the FDA.
- Arrivent’s principal programs are the Phase 3 FURVENT trial in first-line EGFR exon 20 insertion NSCLC and the Phase 1b FURTHER trial, including a fully enrolled PACC-mutation cohort.
- The company also has an early-stage antibody-drug conjugate collaboration with Aarvik and a furmonertinib/ICP-189 combination trial with InnoCare.
- Arrivent began trading on Nasdaq under “AVBP” on January 26, 2024, following its initial public offering.
Financial condition and key metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $64.9 million | $30.4 million | +$34.5 million |
| General and administrative expense | $9.7 million | $6.5 million | +$3.2 million |
| Total operating expenses | $74.6 million | $36.9 million | +$37.7 million |
| Operating loss | $74.6 million | $36.9 million | Loss increased |
| Interest income | $5.3 million | — | +$5.3 million |
| Net loss | $69.3 million | $36.9 million | +$32.4 million |
| Net loss per share | $32.38 | $28.90 | Loss per share increased |
| Cash and cash equivalents at year-end | $150.4 million | $163.4 million | -$13.0 million |
| Net cash used in operating activities | $55.8 million | $43.6 million | Use increased |
| Net cash provided by financing activities | $42.9 million | $169.7 million | Lower financing inflow |
Margins are not meaningful because the company generated no revenue. The company reported total liabilities of $11.8 million, consisting primarily of accounts payable, accrued expenses and operating lease liabilities; the filing does not identify material debt financing. Year-end accumulated deficit was $157.8 million.
Research and development spending was concentrated in furmonertinib: $50.5 million in total, including $25.9 million for FURVENT and $18.9 million for FURTHER. The 2023 FURVENT spending included a $5.0 million clinical milestone payment to Allist.
Material changes versus the prior comparable period
- R&D expense more than doubled as FURVENT and FURTHER advanced, while FAVOUR-related costs declined.
- Net loss increased from $36.9 million to $69.3 million, despite $5.3 million of interest income in 2023.
- Operating cash use increased by $12.2 million to $55.8 million.
- Arrivent raised $44.9 million in net proceeds from Series B preferred stock in 2023, compared with $169.7 million of net financing proceeds in 2022.
- After year-end, the company completed an IPO of 11.18 million shares, including the underwriters’ full over-allotment, at $18.00 per share and received net proceeds of $183.4 million. Preferred stock converted into 19.57 million common shares.
- Cash runway was extended: management expects year-end cash plus IPO proceeds to fund operations into 2026, subject to clinical spending, regulatory timing and other assumptions.
Guidance, outlook, risks and unusual items
- Arrivent expects topline FURVENT Phase 3 data in 2025 and proof-of-concept data from the PACC cohort in FURTHER in 2024.
- The company expects to announce final primary-analysis results from Allist’s FAVOUR study in 2024.
- Management plans a potential PACC registrational program, an adjuvant Phase 3 study targeted to begin enrollment in 2026, and an ADC lead candidate for IND-enabling studies in late 2024 or early 2025.
- Interim FAVOUR data as of June 15, 2023 showed a 79% confirmed response rate in treatment-naive patients, with median duration of response of 15.2 months. These data are preliminary and may change.
- Furmonertinib received FDA Breakthrough Therapy Designation in October 2023 and Fast Track Designation in January 2022; these designations do not assure approval or materially faster development.
- The company remains highly dependent on a single clinical-stage candidate and has incurred losses since inception. It expects additional losses and requires substantial future financing.
- Allist license obligations include up to $105.0 million of additional clinical and regulatory milestones, $655.0 million of sales milestones and tiered royalties ranging from high-single-digit to low-mid-teen percentages on net sales.
- Clinical, regulatory and commercial risks include failure of pivotal trials, safety findings, patient enrollment delays, nonacceptance of foreign clinical data, competition, reimbursement uncertainty and dependence on third-party manufacturers.
- Manufacturing is concentrated with Chinese suppliers Raybow and WuXi STA. Potential BIOSECURE Act restrictions, geopolitical developments or listing actions affecting WuXi could disrupt supply.
- As of December 31, 2023, management identified material weaknesses in internal control over financial reporting related to insufficient accounting resources, manual journal-entry controls and certain non-routine transactions. Remediation was ongoing.
- The filing reports no material cybersecurity incidents during the prior three fiscal years and no material legal proceedings currently pending.
Most important facts for investors to verify
- FURVENT enrollment progress, trial design, topline results and whether efficacy and safety support an FDA submission.
- Final FAVOUR results and whether they confirm or materially revise the interim response and duration-of-response data.
- FURTHER PACC proof-of-concept results and the regulatory path for a potential registrational trial.
- Cash burn, quarterly operating expenses and whether the stated cash runway into 2026 remains valid.
- Potential dilution from the IPO, outstanding options, future financing and registration rights held by pre-IPO investors.
- Allist milestone obligations, royalty economics and the consequences of any license termination or failure to meet development obligations.
- Manufacturing continuity and alternative sourcing plans for suppliers located in China, particularly WuXi STA.
- Progress in remediating the material weaknesses in internal control over financial reporting.